RxDoctor Payments Data

Eva Henry

Wichita, KSNPI 1801810312

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $92,113 of the $100,705 with a category attached, or 91.5%. AbbVie accounts for 95.6% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $25,657 and has fallen 62.0% since, to $9,741 in 2025.

$100,705in general payments, 2019–2025

Across 495 payments — averaging $203.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96K
  • Medtronic$2K
  • Abbott$596
  • Pfizer$557
  • Teva Pharmaceuticals USA, Inc.$439
  • Amgen$222
  • plus $937 from 10 others

What the payments were for

  • Speaking & faculty fees$92,11391%
  • Travel & lodging$2,2432%
  • Food & beverage$5,9036%
  • Education$4470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydromorphone ErHydromorphone Hcl12$9,247
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$584
ProgesteroneProgesterone, Micronized15$442
Citalopram HbrCitalopram Hydrobromide12$2

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →